New Strategies Aim to Cut Graft‑Versus‑Host Disease After Stem Cell Transplants

Researchers are testing fresh ways to keep graft‑versus‑host disease (GVHD) – a dangerous immune attack after blood‑forming stem cell transplants – under control. Recent data compare two drug‑based prevention methods, look at how frozen grafts affect early blood‑cell mixing, and explore a cell‑based therapy for patients whose disease does not respond to standard drugs.

Key takeaways

• Post‑transplant cyclophosphamide (PTCy) lowered severe acute GVHD compared with antithymocyte globulin (ATG) in reduced‑intensity matched‑donor transplants for AML or MDS [1].
• Both PTCy and ATG reduced the chance of extensive chronic GVHD versus no in‑vivo T‑cell depletion, without raising death from other causes or relapse risk [1].
• Freezing donor stem cells was linked to a lower rate of full donor chimerism (≥95% of both blood lineages) on day 60, but did not change overall survival or relapse rates [3].
• An off‑the‑shelf bone‑marrow‑derived mesenchymal stromal cell product (tomostrocel) showed safety and signs of effectiveness in patients with severe, multi‑refractory acute GVHD, especially when early response was seen [2].
• Ongoing trials will clarify whether these approaches can become new standards for transplant safety.

PTCy versus ATG for GVHD prevention

A French registry examined adult patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who received reduced‑intensity conditioning (RIC) matched‑donor peripheral‑blood stem cell transplants. The study compared four groups: PTCy alone, ATG alone, the combination PTCy + ATG, and no in‑vivo T‑cell depletion.

The analysis showed that PTCy alone cut the risk of grade III–IV acute GVHD (the most severe form) by about half compared with ATG (hazard ratio 0.44, p = 0.026) [1]. Both PTCy and ATG also lowered the incidence of extensive chronic GVHD, a long‑lasting form that can damage organs, when measured against the “no‑depletion” group. Importantly, these benefits did not come with higher non‑relapse mortality (death from causes other than disease return) or higher relapse rates [1].

Overall survival at one year was roughly 70 %, progression‑free survival about 62 %, and GVHD‑free, relapse‑free survival (GRFS) close to 48 % across all groups, regardless of donor type or prophylaxis strategy [1]. The authors suggest that PTCy may be a viable alternative to ATG for GVHD prevention in this setting, while awaiting results from randomized trials.

Does freezing the graft matter?

The pandemic pushed many centers to freeze donor stem cells before infusion. A separate French study looked at unrelated donor transplants that used RIC and ATG‑based GVHD prophylaxis, comparing fresh versus cryopreserved grafts.

Cryopreservation was linked to a lower chance of achieving full donor chimerism (≥95 % of both myeloid and lymphoid cells) on day 60—33.8 % for frozen grafts versus 54.4 % for fresh grafts (p = 0.03) [3]. The same analysis found modestly lower early CD3⁺ (T‑cell) chimerism and a slight delay in engraftment, the process when donor cells start making blood.

Despite these early differences, overall survival, progression‑free survival, and GVHD‑free, relapse‑free survival were similar between frozen and fresh groups [3]. The authors conclude that while cryopreservation may affect early chimerism, it appears safe in the context of RIC and ATG prophylaxis, though larger studies are needed.

Mesenchymal stromal cells for refractory acute GVHD

For patients whose acute GVHD does not improve after several standard drugs, options are limited and prognosis is poor. A real‑world analysis collected data on 317 adults treated with tomostrocel, an off‑the‑shelf bone‑marrow‑derived mesenchymal stromal cell (MSC) preparation.

Patients had severe, multi‑refractory disease, meaning they had already failed multiple lines of therapy. The study reported several efficacy signals. Response on day 28 after MSC infusion predicted overall survival, regardless of whether patients had previously received ruxolitinib, a JAK‑inhibitor [2].

Safety was favorable, matching earlier reports of MSC use. No new safety concerns emerged, and the product was well tolerated even in very ill patients [2]. The authors note that, although the data are from a real‑world registry and have inherent limitations, the findings support further investigation in randomized controlled trials that are currently ongoing.

What still needs to be answered

Together, these studies highlight three evolving fronts in GVHD management: (1) drug‑based prophylaxis with PTCy may outperform ATG for severe acute GVHD while both reduce chronic disease; (2) freezing grafts may delay early donor cell dominance but does not seem to harm long‑term outcomes; and (3) MSC therapy offers a potential lifeline for patients whose acute GVHD resists multiple treatments.

Key questions remain. Randomized trials must confirm whether PTCy’s advantage holds in larger, diverse populations and whether combining PTCy with ATG adds benefit. The impact of cryopreservation on immune reconstitution beyond day 60, and its relevance in myeloablative (high‑intensity) regimens, also need clarification. Finally, definitive proof of MSC efficacy will depend on the results of ongoing controlled studies.

Bottom line

Early evidence suggests that post‑transplant cyclophosphamide can cut the most dangerous forms of GVHD without raising relapse or death, while antithymocyte globulin remains a solid alternative. Frozen stem cell grafts may slow early donor blood‑cell takeover but appear safe overall. For patients with GVHD that does not respond to standard drugs, off‑the‑shelf mesenchymal stromal cells show promise and a good safety record. Ongoing trials will determine whether these strategies become new standards for making stem cell transplants safer and more successful.